Bristol-myers Squibb Compnay

Donna Wei

Robert Michael Borzilleri

Heidi L Perez

Gretchen M Schroeder

Zhen-Wei Cai

Andrew J Tebben

Kyoung S Kim

Yong Zhang

Liping Zhang

Andrew Forrest Donnell

Erik M Stang

Sanjeev Gangwar

John S Tokarski

Rajeev S Bhide

Louis John Lombardo

Heng Cheng

Ligang Qian

Stephanie Barbosa

Robert J Schmidt

Tubulysin analogs of the formula (I) where R, RR, R, R, R, R, and Y are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.

Tubulysin analogs and methods of making and use

Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).

Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses

There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

IAP antagonists

There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing said compounds. 

Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds. 

Substituted sulfonamides useful as antiapoptotic Bcl inhibitors

The invention is directed to compounds that are useful for the treatment of cancer having the following Formula: 

Met kinase inhibitors

The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Growing community of inventors

Belle Mead, NJ, United States of America

Donna Wei